NUBURU reports improved finances, targets positive equity by Q2 2026

NUBURU Inc. reported significant financial improvements in its 2025 Form 10-K filing, with cash increasing to approximately $24.7 million from $0.2 million in the prior year, according to a shareholder letter from Executive Chairman Alessandro Zamboni.

The Denver-based defense and security technology company said total assets rose to $49.8 million from $7.0 million, while stockholders' deficit decreased from $(37.8) million to $(15.2) million. The company targets achieving positive shareholders' equity by the second quarter of 2026.

NUBURU has repositioned itself as a dual-use defense and security platform company, moving away from its original laser technology focus. The company operates across multiple business lines including directed-energy systems through its Lyocon subsidiary, software applications via its Orbit platform, and U.S. manufacturing through a joint venture called Maddox.

The company is pursuing a controlling interest in Tekne, an Italian defense contractor, pending regulatory approval. This acquisition would provide NUBURU with established defense customer relationships and electronic warfare capabilities.

NUBURU also disclosed an investment in Heckler & Koch AG as part of its strategy to build partnerships within defense ecosystems while maintaining its focus on non-kinetic technologies and software solutions.

The company stated it has begun initial commercial deployments and entered early-stage revenue generation across its various business segments. NUBURU operates subsidiaries including Nuburu Defense LLC and owns Lyocon S.r.l., which specializes in high-power blue-laser systems.

Founded in 2015, NUBURU trades on public markets and has been executing what it describes as a strategic transformation to address defense, security and operational resilience markets.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Trilogy Metals closes $35.6M investment from U.S. Department of War
• BetterLife Pharma files final prospectus for $100M public offering